Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
Vasculitis
Do you offer biosimilar tocilizumab as an alternative to subcutaneous or infusion brand-name tocilizumab when treating GCA?
Related Questions
Would you continue Rituximab infusions in a patient with GPA and renal involvement who has been in remission on Avacopan and Rituximab, but had PRES post Rituximab infusion?
How long do you continue PJP prophylaxis in a patient with GPA who is able to wean steroids and remains only on rituximab for maintenance therapy?
Would you approach a patient with idiopathic bilateral sensorineural hearing loss and episcleritis as atypical Cogan’s syndrome even in the absence of MRI/ MRA changes and minimal elevation of inflammation markers?
How would you approach peri-operative immunosuppressive management of a patient with Behcet's, currently controlled on azathioprine, who needs genital surgery?
Has anyone successfully gotten insurance approval for avacopan for ANCA-negative GPA?
Do you typically screen every patient with headaches after the age of 60 with ESR?
How do you approach the work up of pulmonary artery aneurysm in the absence of other clinical features of Behcet’s?
How would you approach a pulmonary-renal PR3+ ANCA vasculitis patient who has persistent re-narrowing of mainstem bronchus after several dilatation and stenting procedures, with other anca features well-controlled on rituximab & avacopan?
What additional therapies would you consider in a pregnant woman with Bechet's on an antiTNF and azathioprine who has uncontrolled non-pulmonary large vessel vasculitis?
What is your approach to patients with GCA who have difficulty with prednisone weaning (20mg) despite use of tocilizumab?
